| abstract |
The specification refers generally to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where R1, A1, A2 and A3 have any of the meanings defined herein. The specification also refers to the use of said compounds and salts thereof to treat or prevent a PC-DNA mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising said compounds and salts; kits comprising such compounds and salts; methods of manufacturing said compounds and salts; intermediates useful in the manufacture of said compounds and salts; and to methods for treating a PC-DNA mediated disease, including cancer, using said compounds and salts. |